$RVMD

$RVMD SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #RVMD Revolution Medicines, Inc. : $188.88 Sector: Healthcare |…

$RVMD - Revolution Medicines to Participate in November 2026 Investor Conferences…

$RVMD - Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic…

$RVMD - Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemot…

$RVMD RBC Capital notes Revolution Medicines looks to be down in response to yesterday's disclosure of FDA's Rasonque review documents, particularly t…

$RVMD Truist recommends using today's selloff in shares of Revolution Medicines as a buying opportunity. The firm attributes the pullback to newly dis…

$RVMD - Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line…

$RVMD - zoldonrasib Receives orphan drug designation…

$RVMD - Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for Fir…

$RVMD RevMed Rated New Buy at Morgan Stanley on Oncology Drug Upside, PT $255…

$RVMD - New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Ce…

$RVMD Evercore 320 from 230 HCW 280 from 195…

$RVMD SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #RVMD Revolution Medicines, Inc. : $202.00 Sector: Healthcare |…

$RVMD SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #RVMD Revolution Medicines, Inc. : $203.73 Sector: Healthcare |…

$RVMD SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #RVMD : $181.52 Sector: Healthcare | YTD: 🔼+ 129.77% The SEC dis…